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Abstract
Background: Onchocerciasis is a severe parasitic infestation which causes disabling skin and subcutaneous tissue
changes. Current global estimates suggest that it accounts for 1135.7 disability adjusted life years (DALYs) per
100,000 population. The disease is endemic in many African countries including Cameroon, probably suggesting
that the current health policies are inadequate to achieve eradication of the disease. We aimed to appraise the
current Onchocerciasis control program in Cameroon in the context of existing literature.
Methods: We carried out a MEDLINE search via PubMed to source for articles on Onchocerciasis in Cameroon.
Results: Our appraisal of the literature suggests that Onchocerciasis poses a significant health and economic
burden in Cameroon. A composite of factors contribute to the challenge of containing and eradicating
Onchocerciasis in Cameroon and include: continuous transmission of the disease; non-compliance to mass
drug administration; inability of health care providers (HCPs) to adequately diagnose the disease; limited
access of most individuals in endemic zones to annual preventive chemotherapy and inadequate population
education on simple and practical measures to prevent the disease. More robust population-based epidemiologic
studies are needed to better quantify the current disease burden and consequently guide intervention strategies for
complete disease eradication.
Conclusion: Onchocerciasis is still a neglected tropical disease (NTD) in Cameroon and urgently demands a need
for intensification and probably modification of some strategies in the current onchocerciasis elimination program.
Control of the disease will contribute to achievement of the corresponding Sustainable Development Goals (SDGs)
quota.
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Background
Onchocerciasis is a severe disabling disease with signifi-
cant morbidity in humans due to its debilitating clinical
features [1, 2]. The socioeconomic implications of this
disease cannot be overemphasized as the disease burden
has significant consequences on individuals, communi-
ties and country governments as a whole [3–5].
Onchocerciasis is considered to be a neglected tropical
disease (NTD); and an estimated 99% of all cases of on-
chocerciasis are reported to be from Sub-Saharan Africa
with over 18 million people suffering from the disease
[4, 6]. According to the World Health Organization
(WHO), 6.5 million people who have the disease suffer
from dermatologic manifestations and 270,000 are blind
[4]. The situation in Cameroon is particularly worrisome
as studies have shown that over 60% of the rural popula-
tion is at risk of infection with the disease [6] likely sug-
gesting gaps in public health policies to combat this
NTD [7]. Despite efforts at eradication of the disease
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through annual distribution of Ivermectin, some
onchocerciasis-endemic regions in Cameroon still have a
high prevalence of the disease; with recent studies
reporting a prevalence of 40% in districts in the West
region [8]. In this report, we discuss the merits and
demerits of the current health policies aimed at elimin-
ating this NTD in Cameroon.
Methods
Our review was guided by the following strategy. We
searched MEDLINE via PubMed from inception to
September 2016 to identify studies on onchocerciasis in
Cameroon. The following key words were used:
“neglected tropical diseases”, “disease of poverty”,
“onchocerciasis”, “filariaisis”, “lymphatic filariais”, “river
blindness”, “elephantiasis”, “Onchocerca volvulus”, “black
fly”, “simulium species”, and combined with “Cameroon”.
Reference lists of all articles included were similarly
searched for potential relevant articles. Our search ex-
tended to include abstracts from conference proceedings,
book chapters and documents from organizations such as
WHO, and the United States Centers for Disease Control
and Prevention (CDC). The local Onchocerciasis control
program from the Ministry of Public Health of Cameroon
was also accessed for relevant data. Potentially eligible
articles and documents were further screened to obtain
data regarding the epidemiology and burden of Onchocer-
ciasis (prevalence, incidence, complications/ morbidity
and mortality). We also sourced for data on the economic
burden of the disease to health care systems globally and
Cameroon specifically. The ensuing sections of the review
thus provide a synthesis of a myriad of significant litera-
ture with varied epidemiologic study designs regarding
onchocerciasis in the context of, and appraising the
current NTD – Onchocerciasis control program in
Cameroon.
Results and Discussion
Burden of onchocerciasis in Cameroon
Disability adjusted life year (DALY) estimates due to
onchocerciasis
Globally, there has been a significant decrease in the
disease-burden of Onchocerciasis with the DALYs per
hundred thousand decreasing from 1441.6 in 2005 to
1135.7 in 2015 [9]. However, in a country with a double
disease burden like Cameroon, onchoceriasis contributes
up to 0.63% of the total DALYs with an annual percent-
age change of −3.55% [10]. The situation is worse
amongst those aged 5–14 years with the NTD consisting
of 1.32% of their total DALYs [10]. The burden of the
disease remains a major public health challenge for most
especially endemic African countries. Coffeng and col-
leagues, in their updated estimates of the health impact
of African Programme for Onchocerciasis Control
(APOC) suggested, that the program obviated about 19
million DALYs through 2015, thereby significantly redu-
cing the economic burden of the affection compared to
previous estimates [11]. However, despite this great posi-
tive economic impact of the APOC, they proposed that
the true burden of onchocercal disease was more than
presented in their estimates since they failed to consider
the influence of other sequela linked with onchocerciasis
like epilepsy [12], disfiguring skin disease and the head-
nodding syndrome which has been shown to have a
significant association with the disease especially in Sub-
Saharan Africa [13–15]. Though Cameroon follows the
global trend in the reduction of the burden of the
disease, significant effort is still warranted to achieve
disease eradication.
Epidemiology, prevalence and trends in Cameroon
Onchocerciasis is endemic in several regions in
Cameroon. Despite several years of mass distribution of
Ivermectin, many authors have suggested a decrease in
the prevalence of the disease but a probable non-
interruption of transmission of the disease [6, 16, 17].
This seems to be a significant pitfall towards elimination
and eradication of the disease. In north Cameroon, after
17 years of preventive chemotherapy, researchers in
2010 found a prevalence of positive microfilaria skin
snips of 4.8 and 13.5% of palpable nodules amongst
adults in the community. Furthermore, 5.5% were ob-
served to have microfilariae in the anterior chamber of
the eye [16]. Similarly, in the Western region of the
country, the prevalence of microfilaria in the adult popu-
lation decreased from 68.7 to 11.4% and nodule preva-
lence also decreased from 65.9 to 12.1% after 15 years of
administration of preventive chemotherapy [17]. These
values still suggest though there has been significant re-
duction, transmission still appears to be ongoing with
significantly high infective rates [17]. In the North-west
of the country, lower but significant prevalence were ob-
tained after 7 years of preventive chemotherapy with
3.5% of the population having dermatologic manifesta-
tions of the disease and 3.7% had palpable nodules in a
region where 45% of the population were infected prior
to preventive chemotherapy [4].
Morbidity and complications of onchocerciasis
The disabling clinical features of onchocerciasis range
from severe skin changes to eventual blindness [7]. Indi-
viduals affected with onchocerciasis eventually become
burdens to their communities. This in part is due to the
fact that they may not be able to take part in income
generating activities with consequent dependence on
other community members, and a vicious cycle of
poverty and disease [7]. In Cameroon, the morbidity
due to this disease cannot be understated, with some
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studies showing that over 67.5% of some populations
have visual impairment which could be attributed to
onchocerciasis [4].
Management and prevention of onchocerciasis
Onchocerciasis especially in resource-limited settings is
usually diagnosed from a history of body itches, palpa-
tion of nodules on the skin and a skin snip observed
under a microscope for evidence of larvae of O. volvulus.
Other diagnostic techniques involve observing the anter-
ior chamber of the eye for larvae or characteristic lesions
using a slit-lamp examination, and anti-body tests. In
Cameroon, diagnosis is mostly done by a clinical history
and obtaining a skin snip [9]. Despite the high specificity
of the skin snip testing, low sensitivity values ranging
from 28.6 to 75.6% [18] make it an inadequate diagnostic
test for a country aiming for eradication of the disease
due to the number of individuals who may be missed
especially in the early phase of the disease [18]. Also,
this test requires a high level of technical training, a
resource which is limited in the inaccessible regions of
the country. In addition, the test requires a significant
amount of time to perform. The opportunity cost of the
technicians have to be considered as this time could be
spent doing other cost-effective interventions for the
community.
The standard treatment for onchocerciasis is one dose
of 150 μg/kg of Ivermectin given orally every 6 to
12 months [19].
There are several basic preventive measures which
could help prevent onchocerciasis. These preventive
measures include: wearing long dresses especially in the
evenings, keeping their immediate environments free
from bushes, avoiding settlement in swampy areas and
those with fast flowing rivers and streams [7]. Also, the
population should be encouraged to have good health-
seeking behaviors to allow for early detection of the
disease and hence prevent severe concomitant complica-
tions like blindness [7].
Onchocerciasis and the NTD control program in
Cameroon
Overview of the NTD program
Due to the consequences of onchocerciasis on individ-
uals and communities, several governments have strived
towards the elimination of the disease especially as its
elimination and control was one of the targets of the
Millennium Development Goals (MDGs). The health
burden of onchocerciasis is associated with the nonat-
tainment of the MDGs: 1, 2, 5 and 6 [3]. Due to the
abandonment of fertile lands from fear of the disease,
several communities lived in poverty (goal 1). In
addition, incapacitating skin disease and subsequent
blindness of adult victims lead to them not being able to
provide for their children; sending them to school then
became even more laborious (goal 2). Also, onchocercia-
sis causes severe skin conditions which significantly
affects maternal health and even prevents them from
breastfeeding their newborns (goal 5). Finally, onchocer-
ciasis is a neglected tropical disease which had to be
controlled and eliminated (goal 6) [3]. In Cameroon, the
inability to control the NTDs like onchocerciasis
coupled with other factors like the ever increasing
maternal mortality ratio and poverty levels [7, 20]; could
account for the failure to achieve the above MDGs. With
the advent of the Sustainable Development Goals
(SDGs) [21] there is need for a revamp of health policies
to ensure that Cameroon does not fail to achieve these
goals too.
Most Latin American countries have used expansive
programs to achieve the objective of elimination of
onchocerciasis; with Colombia, Guatemala, Mexico,
Ecuador and Brazil successfully achieving virtual eradica-
tion of onchocerciasis [7, 22]. The use of the Onchocer-
ciasis Elimination Program in the Americas (OEPA)
which combined vector control and annual treatment
using Ivermectin was responsible for this exceptional
achievement in the Americas [22]. However, using this
program as a model has still seen several West African
countries struggle with the elimination of the disease.
The APOC modelled after the OEPA uses biannual dis-
tribution of Ivermectin to vulnerable populations but
does not include vector control due to its relative non
feasibility and reported cost-ineffectiveness [3, 22]. In
Cameroon, the APOC works with the national Neglected
Tropical Diseases Program (NTDP) which was created
to eliminate the disease. The NTDP uses trained non-
medical personnel mostly comprising of community
volunteers to act as Community-directed Distributors
(CDD) of Ivermectin throughout the national territory.
The use of this program has its merits and demerits.
Firstly, the provision of free preventive chemotherapy
(Ivermectin) is easy to be administered in a mass-scale,
and hence, many individuals can have access to this
treatment at no cost. This has great positive conse-
quences on overall health expenditure. Furthermore, the
use of CDD to administer this treatment to communities
is quite effective; in populations where there is a general
mistrust for the health system [23], using trained com-
munity members to provide preventive chemotherapy to
members of their community could be quite helpful as
people (in such areas) would feel relatively comfortable
receiving drugs from fellow community members rather
than from “strangers”.
However this program has several weaknesses. CDDs
do not visit remote and inaccessible areas hence the
people in such regions do not receive annual treatment.
This highlights the fact that several regions in the
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country do not have access to the NTDP [7] even
though, they are endemic to onchocerciasis. To ensure
the success of the program, accessibility to most remote
regions in the country has to be improved. This poten-
tially calls to question whether the number of CDDs is
sufficient as most of the time; only 2 CDDs are available
to cover several large villages and zones. In addition,
there is the problem of compliance to preventive chemo-
therapy even in regions which benefit from the availabil-
ity of CDDs. Studies have shown low compliance to
treatment amongst populations largely due to distrust of
the drug and side effects [24]. In some areas, despite
about 65% coverage by CDDs; over a quarter of these
covered populations do not comply with the treatment
[24]. This problem could potentially be averted by ensur-
ing that CDDs consider amongst others, including and
emphasizing on health education and promotion activ-
ities as their current role seems to be limited to: obtain-
ing treatment from nearby health facilities; distribution
of treatment; taking census; recording of side effects;
treating minor side effects and referring major ones to
more competent health facilities [25].
Furthermore, most HCPs (Health care providers) in
endemic and remote zones somewhat fail to diagnose
onchocerciasis either due to lack of sufficient training;
absence of a highly sensitive diagnostic test or inad-
equate knowledge [7]. If HCPs could effectively diagnose
the disease, they could easily identify and provide data
necessary for mapping out zones that are at risk and en-
demic to the disease. This would inform the necessary
public health authorities of the likely extent of spread of
the disease so that the NTDP could be intensified and
expanded to those areas. This drawback in diagnosing
onchocerciasis coupled with the lack of active surveil-
lance of the disease leads to non-identification of
endemic zones where the NTDP needs to be addressed.
Also, the lack of vector control in West Africa may be a
significant pitfall in the fight against onchocerciasis. In
the Americas, annual distribution of Ivermectin was
coupled with vector control [22]. The success of these
two programs was evident in the virtual elimination of
the disease in most of the concerned countries. Vector
control uses environmentally safe insecticides to kill the
larvae of the Simulium fly (black fly) which is respon-
sible for the transmission of onchocerciasis. This breaks
an important chain in the life cycle of the ‘black fly’;
hence elimination of the parasite is achievable. However,
in endemic zones where vector control is not performed,
despite annual treatment with Ivermectin, there is
always the risk of reinfection as the Black fly continues
reproduction hence the capacity to persistently transmit
the parasite. Therefore in such regions like in Cameroon,
control of the spread of the disease is achievable but
achieving elimination remains doubtful.
Onchocerciasis is directly and indirectly implicated in
the SDGs 1, 2, 3 and 4. As highlighted above, several
individuals are bound to live in poverty due to inability
to farm fertile but swampy lands (Goal 1 and 2); oncho-
cerciasis remains endemic in some areas in Cameroon
(Goal 3) and parents suffering from the disabling condi-
tions of the disease may not be able to send their
children to school (Goal 4).
In Cameroon, there has been a significant improve-
ment in reducing the overall prevalence of onchocer-
ciasis but a proportion of the population remain
infective ensuring that transmission rates remain high.
This represents a significant pitfall towards eradica-
tion of the disease and achievement of the SDGs as a
whole.
Thus to aid in the achievement of the SDGs (and curb
this huge burden related with Onchocercal disease), we
greatly suggest a relook into the onchocerciasis control
program in Cameroon by public health (and policy)
authorities as proposed above to ensure a high level of
effectiveness in the fight to control and eliminate the
disease.
Conclusion
Despite progress made in reducing the prevalence of
onchocerciasis in Cameroon through preventive chemo-
therapy, continuous transmission remains a problem
largely due to problems with compliance. Health policies
that could help salvage this situation include: training
more and improving accessibility of CDDs to remote/
enclaved areas thus intensifying annual preventive
chemotherapy; increasing the number of CDDs available
in the NTDP; providing continuous medical education
programs to HCPs to improve the recognition of the dis-
ease as well as to aid in the identification of high risk
zones; encouraging mass health promotion campaigns
especially in remote areas to inform populations about
preventive measures and the need for compliance to
preventive chemotherapy and finally reconsidering the
use of vector control in highly endemic areas in an
attempt to achieve elimination of the disease.
Key messages
Onchocerciasis is a Neglected Tropical Disease which is
endemic in Cameroon.
The nonattainment of the Millennium Development
Goals could be blamed partly on the failure to
achieve specific targets like the elimination of
Onchocerciasis.
In order to attain the Sustainable Development Goals
and eliminate the disease in Cameroon, we suggest some
re-adaptation of the current health policies and NTD
program.
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